Literature DB >> 10481833

Altered dopamine activity after recovery from restricting-type anorexia nervosa.

W H Kaye1, G K Frank, C McConaha.   

Abstract

When ill, women with eating disorders have disturbances of mood and behavior and alterations of catecholamine activity. It is not known whether these alterations are cause or consequence of pathological eating behaviors. To avoid confounding effects of pathologic eating behavior, we studied women who were recovered (> 1 year, normal weight, regular menstrual cycles, no restricting eating pattern, no bingeing or purging) from anorexia nervosa (AN) and bulimia nervosa (BN) compared to healthy control women. Recovered AN women had significantly lower height-adjusted weight than did recovered BN women. CSF HVA (pmol/ml +/- SD), a major metabolite of dopamine, was significantly lower (p < .02) in six restricting-type AN women (131 +/- 49) compared to 19 BN women (216 +/- 73) and at a trend (p < .08) less than 13 bulimic-type AN women (209 +/- 53, p < .06) and 18 control women (202 +/- 57, p < .08). These four groups had similar values for CSF MHPG, a norepinephrine metabolite. Dopamine neuronal function has been associated with motor activity, reward, and novelty seeking. These behaviors are altered in restricting-type AN compared to other eating disorder subtypes. A trait-related disturbance of dopamine metabolism may contribute to a vulnerability to develop this sub-type of eating disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10481833     DOI: 10.1016/S0893-133X(99)00053-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  45 in total

1.  The multimodal treatment of eating disorders.

Authors:  Katherine A Halmi
Journal:  World Psychiatry       Date:  2005-06       Impact factor: 49.548

Review 2.  Moving towards specificity: A systematic review of cue features associated with reward and punishment in anorexia nervosa.

Authors:  Ann F Haynos; Jason M Lavender; Jillian Nelson; Scott J Crow; Carol B Peterson
Journal:  Clin Psychol Rev       Date:  2020-05-27

Review 3.  Current status of functional imaging in eating disorders.

Authors:  Guido K W Frank; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2012-04-25       Impact factor: 4.861

Review 4.  Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa.

Authors:  A Torsello; F Brambilla; L Tamiazzo; I Bulgarelli; D Rapetti; E Bresciani; V Locatelli
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 5.  Genetics of eating disorders.

Authors:  Anke Hinney; Anna-Lena Volckmar
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

6.  How does zinc supplementation benefit anorexia nervosa?

Authors:  C L Birmingham; S Gritzner
Journal:  Eat Weight Disord       Date:  2006-12       Impact factor: 4.652

7.  Therapeutic approach to eating disorders: the biological background.

Authors:  Palmiero Monteleone; Francesca Brambilla
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

8.  Dopaminergic activity and exercise behavior in anorexia nervosa.

Authors:  Sasha Gorrell; Anne G E Collins; Daniel Le Grange; Tony T Yang
Journal:  OBM Neurobiol       Date:  2020-03-23

Review 9.  Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa?

Authors:  Walter H Kaye; Christina E Wierenga; Ursula F Bailer; Alan N Simmons; Angela Wagner; Amanda Bischoff-Grethe
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

10.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.